![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, July 11, 2011 1:32:49 PM
Minyanville > Markets
Sanofi Tracking Stock Drops on Genzyme MS Drug
By Brett Chase Jul 11, 2011 1:10 pm
Study data doesn't support contention that Lemtrada will take market from other treatments.
At the heart of the standoff over Sanofi’s (SNY) $20 billion takeover of Genzyme was the value of a multiple sclerosis drug.
Genzyme argued that the drug Lemtrada’s market potential was not being recognized in Sanofi’s offering price. After months of back and forth, the two sides agreed on a compromise: a tracking stock that allowed investors to make an individual bet on the MS drug. If the drug met milestones, Sanofi would increase the value of the stock. (See Sanofi Nabs Genzyme.)
This morning, investors are dumping Sanofi’s tracking stock (also known as contingent value right or CVR) on study results of Lemtrada. While the drug appears to work better than an older treatment, Pfizer (PFE) and EMD Serono’s Rebif, the data doesn’t support the contention that Genzyme has a drug that can compete with more recently approved medicines made by Novartis (NVS) and Biogen Idec (BIIB).
RBC Capital Markets analyst Michael Yee predicts Lemtrada will be approved in the US but he considers it as “a last-line agent” to treat MS. In other words, other drugs will be used before doctors prescribe Lemtrada, which means sales will be limited. Novartis’ oral MS drug Gilenya and Biogen’s injectable Tysabri will be prescribed before Lemtrada, Yee says. Lemtrada is an injectable drug.
“Feedback from docs is that (Lemtrada) may be best for aggressive disease but long-term safety will be a concern,” Yee says.
The CVR stock, which trades on Nasdaq as GCVRZ, is down 10% to $2.28 in midday trading Monday. The stock is down almost 3% since it began trading in April.
It would be a stretch to say that Sanofi is a clear winner here. After all, Lemtrada is the French drug maker’s product now. But it’s clear why company execs crafted a deal that reduced its risk on that particular product. Had Sanofi paid Genzyme’s original asking price, it would look foolish now. Instead, the company put some of the risk of the acquisition in the hands of shareholders who chose to hang on to the tracking stock.
Sanofi said it would add up to $14 a share in Lemtrada gets approved and becomes a blockbuster drug. But the drug needs to reach $2.8 billion in annual sales for Sanofi to pay out that full amount.
Celgene (CELG) created a similar CVR stock when it acquired Abraxis BioScience in October for $2.9 billion. That tracking stock (CELGZ) is down 69% since it starting trading and was $1.71 midday Monday.
Don’t be surprised if more big drug companies include -- or try to negotiate -- CVRs in their takeovers of smaller rivals.
Recent SNY News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/11/2024 05:54:55 PM
- I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer • PR Newswire (US) • 06/06/2024 11:00:00 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 05/31/2024 08:30:55 PM
- Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD • GlobeNewswire Inc. • 05/31/2024 05:05:00 AM
- Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation • GlobeNewswire Inc. • 05/31/2024 05:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/30/2024 08:30:57 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/28/2024 04:04:28 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/28/2024 02:34:56 PM
- OpenAI and News Corp Seal Partnership, DuPont de Nemours Announces Division, and More News • IH Market News • 05/23/2024 11:40:51 AM
- CalPERS to Oppose Exxon Mobil Directors; Microsoft Unveils Copilot+ PCs with AI Focus, and More News • IH Market News • 05/21/2024 11:18:35 AM
- Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) • GlobeNewswire Inc. • 05/13/2024 05:00:00 AM
- Novavax Surges 57% Post $1.4 Billion Sanofi Deal; Apple Boosts Data Centers with AI and Internal Chips, and More News • IH Market News • 05/10/2024 12:02:56 PM
- Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines • PR Newswire (US) • 05/10/2024 06:00:00 AM
- Southwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on Earnings • IH Market News • 04/25/2024 11:52:46 AM
- Paramount’s Shares Surge Following Sony and Apollo’s Joint Bid; ISS Backs Berkshire Hathaway Director Re-election, and More • IH Market News • 04/19/2024 11:31:22 AM
- Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)). • Edgar (US Regulatory) • 02/23/2024 07:02:56 PM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/23/2024 04:15:26 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/15/2024 05:09:49 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 08:57:49 PM
- Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE) • GlobeNewswire Inc. • 01/25/2024 07:29:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/23/2024 12:23:49 PM
- Sanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- Update • Dow Jones News • 01/23/2024 11:05:00 AM
- Wall Street Highlights: Vroom Shuts Down Online Car Sales, Ericsson Warns of Decline Outside China, and More • IH Market News • 01/23/2024 10:40:18 AM
- Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B • PR Newswire (US) • 01/23/2024 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/17/2024 06:49:56 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM